Menu ausklappen

Kidney Cancer

The most common type of kidney cancer is renal cell carcinoma (RCC), formerly called hypernephroma, while carcinoma of the ureter and the renal pelvis are less prevalent.

Aside from operations and if applicable, radiation therapy, conventional chemotherapy only plays a minor role in treatment choices. Targeted therapies with angiogenesis inhibitors, which inhibit the growth of new blood vessels, make it impossible for new blood vessels to grow in the tumor. Other drugs block growth signals in the tumor cells: they inhibit important enzymes, the so-called tyrosine kinases. Additionally, antibodies that target specific characteristics of the tumor have been developed.

Immunotherapy is and has been of increased importance in treating kidney cancer, for instance with the use of cytokines, which function as the immune system’s messengers. Other innovative therapeutic approaches are currently being tested in clinical trials and in the framework of compassionate use.

More than 20.000 genomes determine the tumor-biological behavior (growth rate, aggression, metastasis, response to treatment) of any given tumor, yet only a few find consideration in conventional cancer treatment.

While you can see less than 20% of an iceberg above the water line, the discernable amount of treatment-relevant tumor genes ranges only in the part-per-thousands.

New Methods of Analysis Characterize the Tumor

Mit der umfassenden Analyse behandlungsrelevanter Genaktivitätsmuster des Tumors liefert der PANTHER-Test einen wichtigen Beitrag zur Personalisierung der Tumorbehandlung. Der 3D-Spheroid-Chemosensitivitätstest erlaubt eine gezielte Zytostatikatherapie und nicht nur eine Behandlung nach dem Trial-and-Error-Prinzip, bei dem der Patientin/dem Patieten eine starke Einschränkung der Lebensqualität bei unsicheren Erfolgsaussichten zugemutet wird. Dank neuer molekularbiologischer und biomedizinischer Erkenntnisse rücken Target-Therapien (gezielte Krebstherapien) immer mehr in den Vordergrund des medizinischen Interesses. Molekulare Ziele der Target-Therapien sind für individuelle Tumoren charakteristische Mutationen oder erhöhte Aktivitäten von Krebsgenen. Innovative Verfahren wie der PANTHER-Test in Verbindung mit umfassenden Mutationsuntersuchungen der wichtigsten Krebsgene und Tumorsuppressorgene, MultiOnkogenMutationstests (MOMs), entschlüsseln individuelle Krebsgenome bezüglich solcher Merkmale, die für eine Target-Therapie geeignet sind. Solche kombinierten CancerGenomeLandscape Assays stehen je nach Problemstellung in verschiedenen Varianten zur Verfügung.

Histological appearance of renal cell carcinoma

Optimizing Treatments

Liquid biopsies are a new technique in which a tumor and the treatment tailored to it can be assessed without having to undergo an invasive operation. A mere blood sample is enough. Circulating tumor cells (CTCs) or circulating cell-free tumor DNA (cftDNA) form the basis of liquid biopsies. Using special techniques, CTCs can be isolated and offer insight into a procedure’s success rates. Highly efficient molecular biological techniques allow drawing sufficient RNA and DNA from just one or a few of these CTCs to determine the activity of all of the tumor’s genes via the PANTHER-chip test or MultiOncogen Mutation tests (MOMs). Should it be impossible to extract tumor cells from the blood sample, the MOMs can be used to identify therapeutically relevant mutations from circulating cell-free tumor DNA (cftDNA) in the serum. This test is of particular clinical importance since tumors treated with targeted therapy often change their mutational pattern after six months. If this happens, they no longer respond to the current therapy.

Gentle Cancer Treatment via Personalization

The innovations in developing individual vaccines are bringing the dream of personalized, highly specific and gentle cancer therapy closer to realization. New diagnostic tools, pan-genomic PANTHER gene activity testing and EXOM-MOMs make a significant contribution to the development of individual cancer vaccines.

With regard to the production of such vaccines in particular, it can be of critical importance to cryopreserve part of the tumor tissue after an operation. Uomorphis[LvC1]  offers such cryopreservation, either as standard preservation frozen in the gas phase of liquid nitrogen at a temperature of under -190°C or as LIFE-cryopreservation, in which the tumor cells are isolated and frozen alive in a computer-controlled specialized medium.

To determine the best and most promising course of action in your case, you are very welcome to contact Prof. Bojar for a personal consultation.

We are happy to consult you in finding the right treatment for Kidney Cancer!

Testing Methods for Kidney Cancer

CancerGenome Landscape Assay

This most comprehensive molecular-genetic test includes the complete mutational analysis of all human genes that code proteins (exome sequencing) and the activity analysis of the tumor’s entire circa 20.000 genes.

Chemo-/Biopharmaceutical Sensitivity

Using isolated, living tumor cells, this test determines the response to cytotoxic and biopharmaceutical treatments.

MultiOncogen Mutation Tests (MOMs)

MultiOncogen Mutation tests are several, comprehensive mutational tests. When tailored to a specific tumor disease, MOMs identify the mutations relevant to target therapies.

Panther-Test

The most comprehensive of the molecular-genetic tests determines the activity of all of a tumor’s genes. It thus allows evaluating the risk of primary breast cancer (OncoAssay Score) and the response to several possible courses of treatment. Suitable for all kinds of tumors.

zirkulierende Tumor DNA

Circulating Tumor DNA

The test identifies mutations in a tumor’s DNA via serum or plasma. It is used within the real-time mutation analysis in several tumor diseases under targeted therapy (real-time liquid biopsy). It allows for a timely discovery of a tumor’s growing resistance to the targeted therapy.

CTC circulating tumor cells

Zirkulierende Tumorzellen (CTC)

Der Test dient der Bestimmung der Belastung des Blutes durch Tumorzellen. Er erlaubt eine molekulargenetische Charakterisierung der Tumorerkrankung (Real-time liquid biopsy).